Our studies also reveal that Np17 may decrease P53 levels by recruiting nuclear MDM2 to P53 for ubiquitin-mediated degradation in cells, which is frequently dysregulated in AML [39–42]. The gene discussed is TP53; the disease is acute myeloid leukemia.